GANX

Gain Therapeutics Inc

1.98

Jun 29 • 04:00PM ET +0.23 (13.14%)

Healthcare Biotechnology USA Micro NASD

Today, 4:10 PMFDA clears Gain Therapeutics' IND for Parkinson's candidate GT-02287, enabling U.S. Phase 2 trial starting in 3Q26

Peers: ACET ACRV ANIX ATHE ATYR COYA CYPH GOSS INO LONA

| Held by: VXF IWC

Scroll to Statements

Index	-
Market Cap	84.45M
Enterprise Value	68.58M
Income	-21.24M
Sales	0.00M
Book/sh	0.33
Cash/sh	0.39
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	21
IPO	Mar 18, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	6.01
P/C	5.11
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.69
Current Ratio	4.69
Debt/Eq	0.05
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-0.59
EPS next Y	-0.74
EPS next Q	-0.14
EPS this Y	8.68%
EPS next Y	-33.56%
EPS next 5Y	-7.60%
EPS past 3/5Y	25.52% -15.21%
Sales past 3/5Y	- -
EPS Y/Y TTM	33.86%
Sales Y/Y TTM	-
EPS Q/Q	15.90%
Sales Q/Q	-
Earnings	May 11 BMO
EPS/Sales Surpr.	5.45% -

Insider Own	3.00%
Insider Trans	0.00%
Inst Own	19.56%
Inst Trans	-0.12%
ROA	-139.91%
ROE	-214.69%
ROIC	-146.86%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	11.55%
SMA50	8.36%
SMA200	-9.92%
Trades

Shs Outstand	42.49M
Shs Float	41.37M
Short Float	9.35%
Short Ratio	6.63
Short Interest	3.87M
52W High	4.34 -54.38%
52W Low	1.41 40.43%
Volatility	7.25% 6.59%
ATR (14)	0.12
RSI (14)	60.90
Beta	0.19
Rel Volume	16.91
Avg Volume	583.55K
Volume	9,869,825

Perf Week	7.03%
Perf Month	-1.98%
Perf Quarter	8.20%
Perf Half Y	-38.51%
Perf YTD	-38.51%
Perf Year	0.51%
Perf 3Y	-56.00%
Perf 5Y	-80.59%
Perf 10Y	-
Recom	1.00
Target Price	7.20
Prev Close	1.75
Price	1.98
Change	13.14%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$12
Dec-06-24	Initiated	ROTH MKM	Buy	$7
Aug-14-24	Resumed	Oppenheimer	Outperform	$8
Apr-12-21	Initiated	Oppenheimer	Outperform	$30
Apr-12-21	Initiated	BTIG Research	Buy	$30

Today 04:05PM	Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease (GlobeNewswire) +13.14%
Jun-10-26 07:00AM	Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit (GlobeNewswire)
May-26-26 08:00AM	Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026 (GlobeNewswire)
May-11-26 09:51AM	Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss (InvestorsHub)
07:00AM	Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update (GlobeNewswire)
08:30AM	Loading…
Apr-24-26 08:30AM	Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026 (GlobeNewswire)
Mar-26-26 07:00AM	Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update (GlobeNewswire)
Mar-19-26 04:57PM	Gain Therapeutics to Present at the 38th Annual ROTH Conference (GlobeNewswire)
Mar-18-26 08:15AM	Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 (GlobeNewswire) -25.57%
Mar-12-26 07:00AM	Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update (GlobeNewswire)
Feb-19-26 07:00AM	Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-07-26 07:00AM	Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week (GlobeNewswire) -5.49%
Jan-06-26 07:00AM	Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 (GlobeNewswire) -14.14%
Dec-22-25 12:00PM	Gain Therapeutics (GANX) Upgraded to Buy: Here's Why (Zacks) +10.96%
Dec-18-25 04:05PM	Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease (GlobeNewswire) -44.44% +27.78%
09:40AM	Loading…
09:40AM	Is Enhabit, Inc. (EHAB) Stock Outpacing Its Medical Peers This Year? (Zacks)
07:00AM	Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease (GlobeNewswire)
Dec-08-25 12:00PM	Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy (Zacks)
Nov-29-25 01:26AM	Gain Therapeutics' (GANX) Preclinical Momentum Drives Its Progress in Parkinson's Drug Development (Insider Monkey)
Nov-20-25 07:00AM	Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025 (GlobeNewswire)
Nov-17-25 12:00PM	Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-12-25 07:00AM	Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update (GlobeNewswire) +10.07%
Oct-30-25 07:00AM	Gain Therapeutics to Present at Neuroscience 2025 (GlobeNewswire)
Oct-16-25 07:00AM	Gain Therapeutics to Attend the 2025 Maxim Growth Summit (GlobeNewswire)
Oct-09-25 07:00AM	Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease (GlobeNewswire)
Oct-06-25 08:15AM	Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire) +15.63%
Sep-23-25 07:40AM	Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025 (GlobeNewswire)
Sep-18-25 07:41AM	Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease (GlobeNewswire) +7.59%
Sep-04-25 08:00AM	Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation (GlobeNewswire) -9.37%
Aug-12-25 07:00AM	Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update (GlobeNewswire)
08:53AM	Loading…
Jul-24-25 08:53AM	Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference (GlobeNewswire)
Jul-16-25 09:03AM	Gain Therapeutics Announces Pricing of $7.0 Million Public Offering (GlobeNewswire)
Jul-15-25 04:36PM	Gain Therapeutics Announces Proposed Public Offering (GlobeNewswire) -8.60%
Jun-30-25 04:05PM	Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation (GlobeNewswire) -8.63% -12.78%
Jun-10-25 08:00AM	Gain Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-29-25 08:45AM	Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting (GlobeNewswire)
May-14-25 07:30AM	Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update (GlobeNewswire)
May-12-25 07:30AM	Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders (GlobeNewswire)
May-01-25 07:30AM	Gain Therapeutics to Participate at The Citizens Life Sciences Conference (GlobeNewswire) +6.34%
Apr-30-25 07:45AM	Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders (GlobeNewswire) +9.04%
Apr-11-25 02:59PM	Is Gain Therapeutics (GANX) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey) +6.52%
Apr-10-25 07:00AM	Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update (GlobeNewswire)
Mar-28-25 08:30AM	Gain Therapeutics Announces Poster Presentation at AD/PD 2025 (GlobeNewswire) -8.70%
Mar-27-25 07:00AM	Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update (GlobeNewswire)
Mar-14-25 07:45AM	Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease (GlobeNewswire)
Mar-06-25 07:55AM	Gain Therapeutics Announces Oral Presentation at AD/PD 2025 (GlobeNewswire)
Feb-06-25 08:45AM	Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update (GlobeNewswire) +8.20%
Feb-05-25 08:30AM	Gain Therapeutics To Participate in Upcoming Investor Conferences (GlobeNewswire) +10.41%
Jan-16-25 12:00PM	All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy (Zacks) +10.75%
Jan-08-25 08:00AM	Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287 (GlobeNewswire) +7.49%
Jan-07-25 07:00AM	Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director (GlobeNewswire) -6.97%
Dec-25-24 07:40AM	Gain Therapeutics GT-02287 study to deliver positive findings, says Roth MKM (TipRanks)
Dec-23-24 07:30AM	Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease (GlobeNewswire)
Dec-11-24 08:30AM	Gain Therapeutics To Present At Biotech Showcase 2025 (GlobeNewswire)
Nov-14-24 04:05PM	Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update (GlobeNewswire) -14.04% +5.73%
Oct-23-24 08:00AM	Gain Therapeutics Presents Data at 36 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2 (GlobeNewswire)
Oct-15-24 07:00AM	Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-09-24 08:30AM	Gain Therapeutics to Present at Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference (GlobeNewswire)
Oct-07-24 07:00AM	Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024 (GlobeNewswire) +17.31%
Oct-03-24 07:00AM	Gain Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Sep-30-24 07:00AM	Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers (GlobeNewswire) -10.55%
Sep-26-24 07:00AM	Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease (GlobeNewswire)
Sep-19-24 07:00AM	Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024 (GlobeNewswire)
Sep-03-24 07:00AM	Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-30-24 04:52AM	Gain Therapeutics reports positive data from Phase I Parkinsons treatment trial (Clinical Trials Arena)
Aug-29-24 07:30AM	Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease (GlobeNewswire) -20.15%
Aug-08-24 07:30AM	Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update (GlobeNewswire)
Aug-01-24 08:00AM	Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-22-24 07:00AM	7 Sorry Biotech Stocks Set to Make Investors Sad (InvestorPlace)
Jul-09-24 07:00AM	Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease (GlobeNewswire) +5.36%
Jul-08-24 12:00PM	Gain Therapeutics (GANX) Upgraded to Buy: Here's Why (Zacks) -6.67%
Jun-28-24 04:39PM	Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024 (GlobeNewswire) -12.50%
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-27-24 04:08PM	Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO (GlobeNewswire)
08:35AM	Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson's disease (GlobeNewswire)
Jun-25-24 07:00AM	Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
Jun-14-24 08:37AM	Why Is Gain Therapeutics (GANX) Stock Down 25% Today? (InvestorPlace) -34.39%
07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-13-24 09:00PM	Gain Therapeutics Announces Pricing of $11.0 Million Public Offering (GlobeNewswire) -10.43%
04:44PM	Gain Therapeutics Announces Proposed Public Offering (GlobeNewswire)
May-30-24 07:00AM	Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024 (GlobeNewswire) +5.46%
May-14-24 01:54PM	GANX Stock Earnings: Gain Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update (GlobeNewswire)
May-03-24 10:00AM	Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-24-24 09:25AM	Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease (GlobeNewswire) -5.90%
Apr-17-24 09:55AM	Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher (Zacks)
Apr-10-24 03:30PM	Insiders are Piling into These 10 Healthcare Stocks in 2024 (Insider Monkey)
09:35AM	Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX) (Zacks)
Apr-08-24 09:25AM	Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer (GlobeNewswire)
Apr-02-24 05:40PM	Insiders Are Buying These 5 Penny Stocks (Insider Monkey)
Apr-01-24 07:01PM	Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX) (GuruFocus.com)
09:25AM	Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
Mar-26-24 01:53PM	GANX Stock Earnings: Gain Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
08:00AM	Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update (GlobeNewswire)
Mar-15-24 02:30PM	Gain Therapeutics to Present at Public Ventures Discovery Day (GlobeNewswire)
Mar-05-24 09:45AM	EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease (Benzinga)
08:00AM	Gain Therapeutics Presents Data at the AD/PD 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson's Disease (GlobeNewswire)
Feb-27-24 02:00PM	Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease (GlobeNewswire)
Feb-14-24 12:29PM	Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insight (GlobeNewswire)
Feb-06-24 09:56AM	UPDATE - Gain Therapeutics' GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson's Disease (GlobeNewswire)

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never targeted before. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Chairman & FounderDr. Khalid Islam Ph.D.

PresidentMr. Gene Mack M.B.A.

Senior VP of Finance & Principal Financial OfficerMr. Gianluca Fuggetta

Senior Vice President of Technical OperationsDr. Terenzio Ignoni Pharm.D.

Senior Vice President of ResearchDr. Joanne Taylor Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

GANX

Gain Therapeutics Inc

Upgrade your Finviz experience